Fluzone Procurement Guide for the 2026–27 Flu Season
Updated August 2026
Seasonal influenza vaccine procurement involves more than confirming product availability. Healthcare organizations must align inventory planning with annual formulation updates, FDA-approved labeling, CDC ACIP recommendations, storage requirements, patient demographics, and internal vaccination protocols.
For the 2026–27 U.S. influenza season, Fluzone is supplied as a trivalent, egg-based inactivated influenza vaccine. FDA-approved labeling identifies Fluzone as an influenza vaccine indicated for active immunization for preventing disease caused by influenza A subtype viruses and influenza B virus contained in the vaccine. It is approved for individuals 6 months of age and older.
This guide is designed for licensed healthcare professionals, purchasing teams, practice administrators, vaccine coordinators, and clinical procurement stakeholders. It covers product formulation, available presentations, current ACIP considerations, storage requirements, and operational planning. It does not replace FDA-approved prescribing information, CDC/ACIP recommendations, or patient-specific clinical judgment.
Why Season-Specific Review Matters
Influenza vaccines are unusual among commonly stocked clinical products: their antigen composition changes annually. A familiar product name can represent a newly formulated vaccine each season.
For procurement teams, this distinction is critical. Ordering teams must verify that incoming inventory corresponds to the 2026–27 formula, not earlier seasons.
In March 2026, FDA’s Vaccines and Related Biological Products Advisory Committee reviewed surveillance, antigenic, epidemiologic, and manufacturing data before recommending influenza virus components for the 2026–27 U.S. season. This annual process affects:
- standing order templates
- electronic health record references
- inventory records
- staff education materials
- storage and administration workflows
The goal is to maintain a procurement process that supports product identification, traceability, appropriate storage, and use according to current labeling and clinical guidance.
The 2026–27 Fluzone Formulation
Fluzone Is Trivalent for 2026–27
The 2026–27 Fluzone formula contains three influenza virus components: two influenza A and one influenza B/Victoria lineage component.
FDA recommended the following 2026–27 egg-based strains:
| Influenza Component | 2026–27 Egg-Based Recommended Virus |
|---|---|
| Influenza A(H1N1) | A/Missouri/11/2025 (H1N1)pdm09-like virus |
| Influenza A(H3N2) | A/Darwin/1454/2025 (H3N2)-like virus |
| Influenza B | B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus |
All three components differ from the prior Northern Hemisphere season, making season-specific verification particularly important for 2026–27.
Why U.S. Vaccines Are Now Trivalent
The transition to trivalent influenza vaccines did not begin in 2026. U.S. seasonal vaccines shifted from quadrivalent to trivalent beginning with the 2024–25 season.
Quadrivalent vaccines previously included one H1N1, one A(H3N2), one B/Victoria, and one B/Yamagata lineage component. Global surveillance found no confirmed circulating B/Yamagata lineage virus detections after March 2020. FDA recommended removing that component, and U.S. vaccines transitioned accordingly.
For procurement teams: the 2026–27 Fluzone formula is intentionally trivalent. The absence of a B/Yamagata component does not indicate an incomplete product or that a quadrivalent alternative should be substituted.
Available Fluzone Presentations for 2026–27
FDA’s July 2026 Fluzone prescribing information identifies two standard-dose presentations: a 0.5 mL single-dose prefilled syringe and a 5 mL multiple-dose vial.
| Presentation | Dose Approval | Preservative | Procurement Note |
|---|---|---|---|
| 0.5 mL single-dose prefilled syringe | 6 months and older | No thimerosal | Aligns with current ACIP recommendation for single-dose, thimerosal-free formulations |
| 5 mL multiple-dose vial | 6 months and older | Contains thimerosal (25 mcg per 0.5 mL dose) | FDA-labeled but no longer recommended under current ACIP guidance |
Single-Dose Prefilled Syringe (0.5 mL)
The 0.5 mL prefilled syringe is manufactured without thimerosal or other preservatives.
Current CDC guidance lists this presentation for individuals 6 months and older. For children 6 through 35 months, FDA-approved dosing includes either 0.25 mL or 0.5 mL. For individuals 36 months and older, the labeled dose is 0.5 mL.
Critical point for pediatric practices: The availability of only a 0.5 mL syringe does not mean Fluzone cannot be used in children 6 through 35 months. A 0.5 mL dose is one of the FDA-approved options for this age group.
Clinical staff must still determine the appropriate dose schedule based on current ACIP guidance, vaccination history, FDA labeling, and applicable clinical protocols.
0.25 mL Prefilled Syringe (Discontinued)
The 0.25 mL Fluzone prefilled syringe is no longer available. This does not eliminate the FDA-labeled 0.25 mL dose option for children 6 through 35 months.
Practices serving pediatric populations should update purchasing assumptions, standing procedures, and clinical references to reflect the current presentation lineup.
Multiple-Dose Vial (5 mL)
The 5 mL multiple-dose vial remains FDA-labeled and permits withdrawal of up to ten doses.
Unlike the single-dose syringe, this vial contains thimerosal as a preservative. Each 0.5 mL dose contains 25 micrograms of mercury from thimerosal; each 0.25 mL dose contains 12.5 micrograms.
A key distinction: the vial remains FDA-licensed while current ACIP recommendations favor single-dose formulations free of thimerosal. CDC’s vaccine table identifies the multiple-dose vial as a labeled presentation no longer recommended under current guidance.
Practices should use current ACIP recommendations together with FDA labeling and internal policies when developing seasonal purchasing plans.
How Patient Demographics Affect Procurement
Vaccine procurement should start with the population a healthcare organization expects to serve. Product availability alone does not determine an appropriate inventory mix.
Pediatric Practices
Pediatric practices should account for patient age distribution and anticipated vaccination history.
FDA labeling permits either 0.25 mL or 0.5 mL Fluzone for children 6 through 35 months. Depending on prior vaccination history and age, some children may require more than one dose during the season. Current ACIP recommendations guide whether one or two doses are appropriate for each child.
Practices serving pediatric populations should forecast expected dose requirements, which may exceed the number of individual patients when some children require two doses.
Adult Practices (Adults Younger Than 65)
Standard-dose Fluzone is approved for individuals 6 months and older, making age eligibility broad. Product selection should also consider patient-specific contraindications, current ACIP recommendations, and organizational protocols.
Operationally, demand forecasting may rely on prior seasonal administration patterns, appointment volume, employer vaccination programs, and anticipated vaccination timing.
Practices Serving Adults 65 Years and Older
Adults aged 65 and older require specific procurement attention.
Current CDC guidance states that this age group should preferentially receive one of three vaccine types: high-dose inactivated, recombinant, or adjuvanted inactivated influenza vaccine. Named options include Fluzone High-Dose, Flublok, and Fluad. If none of the preferred options is available, another age-appropriate influenza vaccine may be used.
Standard-dose Fluzone and Fluzone High-Dose are separate, labeled products with different specifications. Procurement documentation should not treat them as interchangeable.
A practice serving substantial numbers of patients aged 65 and older should incorporate this preferential recommendation before determining its seasonal inventory mix.
Mixed-Age Practices
Mixed practices may benefit from deliberate inventory modeling since a single product selection may not equally serve every patient subgroup.
Consider:
- proportion of pediatric, adult, and older adult patients
- anticipated dose requirements for each group
- clinician product-selection protocols
- refrigerated storage capacity
- expected administration timing
This planning should occur before committing storage capacity to seasonal inventory.
Storage and Cold-Chain Requirements
Cold-chain maintenance is essential because vaccine remains usable only when storage requirements are met.
Current FDA prescribing information requires refrigeration at 2°C to 8°C (35°F to 46°F). Fluzone must not be frozen, and frozen vaccine should be discarded. The multiple-dose vial should be returned to refrigerated conditions between uses. Vaccine should not be used after the expiration date on the label.
Before ordering, confirm adequate refrigerated capacity for the anticipated quantity and presentation. Procurement and clinical operations teams should verify that:
- temperature-monitoring procedures are current
- receiving workflows document arrival conditions
- escalation protocols address temperature excursions
- inventory rotation procedures are active
Update internal materials containing older storage language or different Fahrenheit conversions to match current FDA prescribing information.
Building a Traceable Procurement Workflow
Procurement controls support both operational efficiency and product accountability.
A vaccine purchasing workflow should allow your organization to determine:
- what product was ordered
- when it was received
- applicable lot or batch information
- storage location and conditions
- how inventory moved through the organization
For seasonal products like influenza vaccines, traceability also confirms use of the correct season’s formulation. Packaging, labeling, invoices, receiving records, and inventory systems should distinguish 2026–27 inventory from records for earlier seasons.
Pipeline Medical’s verified procurement platform provides authorized sourcing for licensed medical professionals. All products undergo manufacturer verification, batch traceability, and FDA-compliant handling from warehouse to clinic.
Procurement documentation does not replace clinical documentation. Vaccine administrators remain responsible for patient records, administration documentation, Vaccine Information Statements, and applicable regulatory requirements.
A Practical 2026–27 Procurement Checklist
Before finalizing seasonal inventory, conduct a documented review covering:
- Verify the season and formulation. Confirm that purchased Fluzone inventory is designated for 2026–27 and corresponds to the current trivalent formulation.
- Confirm the presentation. Distinguish the 0.5 mL single-dose prefilled syringe from the 5 mL multiple-dose vial and verify preservative status.
- Review current ACIP guidance. CDC recommends single-dose formulations free of thimerosal as a preservative.
- Assess patient demographics. Estimate vaccination volume by age group. Pay particular attention to children who may require two doses and adults aged 65 and older covered by preferential vaccine recommendations.
- Verify cold-storage capacity. Confirm sufficient refrigerated space at 2°C to 8°C (35°F to 46°F) with appropriate temperature monitoring.
- Maintain traceability. Retain ordering, receiving, lot, storage, and inventory information according to organizational and regulatory requirements.
- Recheck labeling before administration begins. Review current FDA prescribing information and CDC/ACIP materials rather than relying only on earlier procurement documents.
Safety and Labeling Information for Healthcare Professionals
Current Fluzone prescribing information states that the vaccine should not be administered to individuals with a history of severe allergic reaction, including anaphylaxis, to any vaccine component (including egg protein) or following a previous influenza vaccine dose.
The labeling further states:
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions
- Careful consideration of benefits and risks applies when Guillain-Barré syndrome occurred within six weeks of previous influenza vaccination
- Syncope has been reported following administration
The July 2026 prescribing information includes updated warning language concerning febrile seizures in young children following certain prior-season standard-dose influenza vaccines. Healthcare professionals should review the complete current prescribing information rather than relying on procurement materials for evaluation of warnings, precautions, adverse reactions, and patient-specific considerations.
No vaccine is effective for every recipient. FDA labeling includes a limitation-of-effectiveness section. Product selection and administration should remain under qualified clinical supervision.
Aligning Procurement With Clinical Operations
A vaccine procurement program works most effectively when purchasing, receiving, storage, and clinical teams use the same current product information.
Before the vaccination campaign begins:
- Align purchasing records with clinical protocols
- Ensure staff understand which presentations were ordered
- Update legacy references showing the discontinued 0.25 mL syringe
- Correct materials that still reference quadrivalent formulations
Clinical teams should also distinguish standard-dose Fluzone from Fluzone High-Dose. Similar product names should not replace verification of exact labeled product, presentation, age indication, dose, and current ACIP recommendation.
For pediatric settings, account for vaccination schedules that may require more doses than the number of individual patients. For practices serving older adults, account for ACIP’s preferential recommendation for specific vaccine types in patients aged 65 and older.
Procurement makes appropriately sourced and stored inventory available. Licensed healthcare professionals determine whether and how a vaccine should be administered to an individual patient.
Frequently Asked Questions
Is Fluzone trivalent for 2026–27?
Yes. Fluzone is trivalent for 2026–27, corresponding to FDA-recommended A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like, and B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus components.
Why is B/Yamagata not included?
U.S. influenza vaccines returned to trivalent formulations beginning with the 2024–25 season. FDA and CDC materials confirm that the B/Yamagata component was removed after global surveillance identified no confirmed circulating B/Yamagata lineage viruses after March 2020. The B/Victoria lineage remains represented in current trivalent vaccines.
Is the 0.25 mL prefilled syringe available?
No. Current CDC guidance states that the 0.25 mL prefilled syringe is no longer available. This does not eliminate the FDA-approved 0.25 mL dose option for children 6 through 35 months. The available 0.5 mL prefilled syringe falls within the labeled dose options for this age group.
What dose is approved for children 6 through 35 months?
FDA labeling permits either 0.25 mL or 0.5 mL for individuals 6 through 35 months. Whether one or two doses are required during the season depends on vaccination history and current clinical recommendations. The label directs clinicians to ACIP’s annual recommendations when determining the applicable schedule.
What dose is used starting at 36 months of age?
Current FDA labeling identifies a 0.5 mL dose for individuals 36 months and older.
Does the Fluzone multiple-dose vial still exist?
Yes. FDA’s current prescribing information lists a 5 mL multiple-dose vial containing thimerosal. Current CDC/ACIP guidance recommends single-dose formulations free of thimerosal, so the vial’s labeled availability should be distinguished from current recommendations.
Does the single-dose syringe contain thimerosal?
No. The 0.5 mL single-dose prefilled syringe is manufactured without thimerosal or other preservatives.
Are there different recommendations for adults 65 and older?
Yes. Current CDC guidance preferentially recommends high-dose inactivated, recombinant, or adjuvanted inactivated influenza vaccine for adults aged 65 and older. Fluzone High-Dose is one of the preferred options. If none is available, another age-appropriate influenza vaccine may be used.
Is standard-dose Fluzone the same as Fluzone High-Dose?
No. They are distinct products with separate labeling. Standard-dose Fluzone is the product discussed throughout this article unless otherwise noted. Fluzone High-Dose is one of the influenza vaccines preferentially recommended by ACIP for adults aged 65 and older.
How should Fluzone be stored?
Current FDA labeling requires refrigeration at 2°C to 8°C (35°F to 46°F). The product must not be frozen, and frozen vaccine should be discarded. Consult the current prescribing information for complete storage and handling instructions.
How much Fluzone should a practice order?
Practices should consider expected patient volume, age distribution, applicable dose schedules, current ACIP recommendations, available presentations, refrigerated storage capacity, administration timing, and internal inventory requirements. Procurement quantity should be determined by the healthcare organization rather than by a generalized formula.
Ready to Finalize Your Seasonal Procurement?
The 2026–27 influenza season requires working from current product information, not assumptions from earlier years. Fluzone is a trivalent, egg-based influenza vaccine for 2026–27, with FDA-approved presentations including the 0.5 mL preservative-free single-dose syringe and the 5 mL multiple-dose vial.
Current ACIP recommendations favor single-dose formulations free of thimerosal, and practices serving older adults should account for preferential vaccine recommendations for that age group.
Connect with Pipeline Medical’s procurement team to review your seasonal inventory requirements, confirm current formulation alignment, and finalize your ordering plan. Our team supports licensed practices with accurate product information, verified sourcing, and compliant fulfillment for the complete 2026–27 season.
The information provided on this site is for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider or medical professional for guidance on any medical concerns, product use, or treatment decisions.
Trademark Footnote
Fluzone is a registered trademark of Sanofi Vaccines US Inc. All other trademarks are the property of their respective owners.